<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220076</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 08/11-A</org_study_id>
    <nct_id>NCT01220076</nct_id>
  </id_info>
  <brief_title>Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+</brief_title>
  <acronym>TAM</acronym>
  <official_title>Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The biological response to treatment with tamoxifen in the preoperative situation is studying&#xD;
      in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +.&#xD;
&#xD;
      The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of&#xD;
      TAM will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the response to Tamoxifen treatment, in preoperative situations (immediately operable patients) in patients with positive Hormone Receptors (HR+) non-metastatic breast cancer</measure>
    <time_frame>5 weeks</time_frame>
    <description>The primary endpoint is the determination of the variation in the KI-67 expression, a marker of cell proliferation, at the tumour level between the initial biopsy (T0) and after 5 weeks of tamoxifen treatment, in relation to cytochrome 2D6 polymorphisms. A 50% geometric reduction in KI-67 expression at 5 to 7 weeks should be considered as a major response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Non Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <arm_group_label>Tamoxifene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Females (≥ 18 years), with effective contraception. The contraceptive should not&#xD;
             use estrogen to a derivative. It must be continued during treatment with tamoxifen for&#xD;
             at least two months after his arrest.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of invasive breast cancer, previously untreated.&#xD;
             Patients have been supported for a breast cancer may be included if a period of at&#xD;
             least 2 years between the last systemic treatment of inclusion in the study.&#xD;
&#xD;
          -  Primary tumor hormonopositive: ER and / or PR ≥ 50% by immunohistochemistry.&#xD;
&#xD;
          -  Lack of HER2 overexpression&#xD;
&#xD;
          -  Palpable primary tumor or greater than or equal to 20 mm in diameter, measured by&#xD;
             ultrasound&#xD;
&#xD;
          -  Patient scheduled to undergo breast cancer surgery&#xD;
&#xD;
          -  No metastases&#xD;
&#xD;
          -  Clinical Stage M0&#xD;
&#xD;
          -  Performance index ≤ 1 (OMS)&#xD;
&#xD;
          -  Neutrophils WBC &gt; or = 1500 / mm3, Platelets &gt; or = 100 000/mm3 Hemoglobin ≥10 g/dL&#xD;
&#xD;
          -  Normal liver function: bilirubin ≤ 1.5 x ULN, aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases).&#xD;
&#xD;
          -  Normal renal function (creatinine ≤ 1.5 mg / dL or creatinine clearance ≥ 60 mL / min)&#xD;
&#xD;
          -  Cardiac function (MUGA scan or ultrasound February&gt; 55%) and lung function, 5.2.2&#xD;
             Criteria related to participation in the study:&#xD;
&#xD;
          -  Patient affiliated to social security, Patient has signed and dated consent&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant or Breastfeeding women&#xD;
&#xD;
          2. Use of St. John's Wort (herbal tea ...) within 5 days before starting treatment&#xD;
&#xD;
          3. Consumption of grapefruit juice in the last 5 days of starting treatment&#xD;
&#xD;
          4. Congenital galactosemia&#xD;
&#xD;
          5. Glucose and galactose malabsorption&#xD;
&#xD;
          6. Lactase deficiency&#xD;
&#xD;
          7. Co-medications that may interfere with cytochrome P450:&#xD;
&#xD;
          8. Ongoing Enzyme inducers:&#xD;
&#xD;
               -  Antiepileptic drugs: carbamazepine, phenobarbital, phenytoin&#xD;
&#xD;
               -  Antinfectieux: rifampin, rifabutin, névrirapine, griséofilvine, efavirenz&#xD;
&#xD;
          9. Ongoing Enzyme Inhibitors:&#xD;
&#xD;
               -  Inhibitors of serotonin reuptake: fluoxetine, paroxetine&#xD;
&#xD;
               -  Thioridazine. Quinidine&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Ca antagonists: diltiazem, verapamil&#xD;
&#xD;
               -  azole antifungals ketoconazole, fluconazole, miconazole.&#xD;
&#xD;
               -  No protease inhibitors: ritonavir, nelfinavir, amprenavir, indinavir.&#xD;
&#xD;
               -  Macrolides: erythromycin, clarithromycin, josamycin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO)</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamoxifen,</keyword>
  <keyword>Breat Cancer</keyword>
  <keyword>Pharmacogenetic</keyword>
  <keyword>non metastatic breast cancer, HR +</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

